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Screening for disease e The good e The bad
and the thoughtfulWilson and Jungner1 laid down 10 principles of
screening in 1968:
1. The disease should be an important public
health problem.
2. There should be an accepted treatment for
patients with recognized disease.
3. Facilities for diagnosis and treatment should
be available.
4. There should be a recognizable latent or early
symptomatic stage.
5. There should be a suitable test or examination.
6. The test should be acceptable to the popula-
tion.
7. The natural history of the disease, including
development from latent to declared disease,
should be adequately understood.
8. There should be an agreed policy on whom to
treat as patients.
9. The cost of case-finding, including diagnosis
and treatment of patients diagnosed should be
economically balanced in relation to possible
expenditure on medical care as a whole.
10. Case-finding should be a continuing process
and not a ‘‘once and for all’’ project.
No test fulfils all these requisites. The minimum
requirements could be, therefore, said to be the
following. An ideal screening test should be looking
for a disease that has a great impact that could
be demonstrably averted by earlier treatment,
usually by reducing mortality. It should be highly
sensitive and specific. It should be cheap and
easily administered. At the very least, it should
prevent the devastating effects of advanced dis-
ease. In any case, an informed consent should be
mandatory before an individual begins screening.1743-9191/$ - see front matter ª 2005 Surgical Associates Ltd. Pub
doi:10.1016/j.ijsu.2005.06.001Examples of such tests are rare. Heel-prick
blood test for the metabolic disorders such as
phenylketonurea and congenital hypothyroidism
has probably prevented many cases of mental
retardations and cretinism. A more surgical exam-
ple is ultrasonographic screening for aortic aneur-
ysms. The natural history of abdominal aortic
aneurysm (AAA) above a certain size could almost
be determined by physical laws alone, making
rupture is almost inevitable. So prevention of such
a dramatic and painful death is an obvious target.
A recent meta-analysis by the US task force2
suggests that screening reduces AAA-related mor-
tality. Intervention is necessary in less than 5% of
the screened group and the number needed to
screen to save one life ranges from 350 to 700. An
estimate of the financial cost of saving a life-year
(after 10 years) comes to a modest £8000/-,3 less
than the cost of a good car! The human cost to
someone undergoing screening is complex. If the
ultrasonography reveals a large aneurysm, the
person needs to decide to either accept the in-
tervention e open or even endoluminal repair with
its complication risks, which are not insignificant,
or take the much higher risk of rupture. So in
theory, the consent for screening would be
straightforward and Chancellor of the Exchequer
willing, this could be a good example of success of
screening.4
Screening for cancer
However, screening for a malignant tumour is not
so straightforward and the rest of this paper will
address the issue of screening for solid tumours
with some illustrative examples.lished by Elsevier Ltd. All rights reserved.
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its natural history can be significantly modified by
treatment. So in theory any cancer that is curable
when treated early, usually by surgery, and incur-
able later, would be suitable for screening. How-
ever, we do not fully understand the process of
carcinogenesis and metastasis, nor do we have
efficient (as opposed to ‘reasonably effective’)
treatment for most common malignant tumours.
The other ‘problem’ is the large difference in
biological behaviour of a cancer in people d from
rapid progression to spontaneous regression. Let us
discuss the success stories first.
The good
Screening for cervical cancer with a PAP smear is
the epitome of a screening test. It is cheap, easy to
administer, and sensitive. It certainly has resulted
in down-staging of cervical cancer and may have
even reduced mortality.5,6 Of course, there is
overdiagnosis of cervical intraepithelial neoplasia,
but there is little social taboo associated with its
diagnosis, its treatment is not mutilating and
usually completed in an outpatient setting. Hence,
the human cost of this overdiagnosis is not high, if
one discounts the high profile and expensive law-
suits from ‘missed diagnosis’. But that is the
subject of a different and ethical/moral debate.
Screening for colorectal cancer with faecal
occult blood (FOB) testing followed by colonoscopy
reduces mortality by 11%.7 The FOB test is simple
to administer and only about 5% of those screened
needed to undergo colonoscopy. In the Scandina-
vian study, those who attended all 9 biennial
screening rounds had a 43% reduction in mortality
and importantly, the survival of patients diagnosed
between screens (interval cancers) had better
survival than controls. The incidence of colorectal
carcinoma did not increase in the screened group,
suggesting that there was little, if any overdiag-
nosis. The success of screening for colorectal
cancer suggests that surgery is curative in a signif-
icant proportion of colorectal cancers and early
surgery has a significantly higher impact than later
surgery. The fact that colorectal cancer does not
usually recur after first few years of primary
treatment corroborates this contention.
Screening for oral cancer by looking in the
mouth is an elegant demonstration of common
sense! A recent study from India8 revealed that
this simple and easily taught manoeuvre has high
sensitivity, high specificity and appears to save
lives. When this is implemented it will be a yet
another successful battle before the war on thetobacco industry is won and the tobacco plant goes
the way of small pox virus (Table 1).
The bad
Neuroblastoma is the second most common child-
hood solid tumour and is a classic example of
natural regression that was unearthed because of
screening. Screening for neuroblastoma is easy e
a urine test at 6 months of age for vanillylmandelic
acid and homovanillic acid (metabolites of the
noradrenaline and dopamine). Contrary to all
expectations, screening for neuroblastoma in in-
fants only increases the incidence of early-stage
neuroblastoma,9,10 without a concurrent reduction
of advanced-stage disease, or of any disease in
older children. The cases identified by screening
almost exclusively have biologically favourable
properties. This leads to unnecessary diagnostic
and therapeutic procedures with consequent phys-
ical and psychological morbidity, including death
from treatment complications. When natural re-
gression was so clearly demonstrated, screening
for neuroblastoma was abandoned.
Screening for lung cancer with spiral-CT11 scans
in Japanese populations uncoveredmany small lung
cancers at a rate much higher than population
incidence of clinical cancer. Many of these were of
course curable, but was the diagnosis-and-cure
unnecessary?Only half of these cancerswere among
smokers compared with 95% of clinical tumours.
This discrepancy is too large to ignore12 and suggests
that most of these sub-clinical cancers would never
have progressed to clinical disease. It is estimated
that even in the highest risk group with the most
effective spiral-CT, screening would not be cost
effective,13 using a threshold of about £30000/- per
life-year gained. Screening for lung cancer is really
an irony when 95% of it could be prevented by
tobacco eradication!
Thinking maketh it so
The case of breast and prostate cancers is differ-
ent and for different reasons. Both diseases are
common and share hormonal aetiology in respec-
tive sexes, although the exact cause is not known
and treatment can have devastating physical and
psychological effects.
The story of prostate cancer appears to be much
clearer today than ever before. It is the only major
cancer in which the effectiveness of surgery itself
has been tested. Recent results from the Swedish
randomised trial14e16 of watchful waiting vs. rad-
ical prostatectomy proved that surgery reduced
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Natural history Diagnosis of
fatal disease
at curable stage?
Screening tool Curative
intervention
Human cost
Neuroblastoma Spontaneous
regression or
aggressive
behaviour
No Simple urine test Aggressive and
potentially
hazardous
Higher than
the benefit
Cervical cancer Slow growth,
with some
natural
regression
Yes Relatively
non-intrusive
smear test
Relatively
harmless
Lower than
benefit
Lung cancer Aggressive
growth
Unlikely Expensive and
possibly hazardous
Aggressive Very high
financial costs
Colorectal
cancer
Relatively slow
growth and
orderly spread
Yes Simple FOB test Relatively
non-aggressive
Lower than
the benefit
Oral cancer Recognisable
precancerous
conditions and
mainly local
spread
Yes Simple oral
inspection
Relatively
non-aggressive
Lower than
the benefit
Breast cancer Chaotic growth
and spread
Yes, but
unpredictable
Complex and
subjective
Relatively
non-aggressive
Very high and an
informed decision to
screen or not should
be left to those being
screened
Prostate
cancer
Slow growth Yes Simple blood test Aggressive
with many
complications
Very high and an
informed decision to
screen or not should
be left to those being
screeneddisease-specific mortality as well as overall mor-
tality at 8-year follow-up. There is balance of
costs: erectile dysfunction (80% vs. 45%) and
urinary leakage (49% vs. 21%) after radical prosta-
tectomy, vs. urinary obstruction (e.g., 44% vs. 28%
for weak urinary stream) and death (14.4% vs.
8.7%) with observation. It, therefore, should follow
that screening for prostate cancer with PSA would
work. We need to wait another 7 years until the
results of the Prostate, Lung, Colorectal and
Ovarian (PLCO) Cancer Screening Trial are avail-
able. In this trial, at the end of the first screening
round, 7.5% of men had a positive digital rectal
examination and 7.9% had a PSA level higher than
4 ng/m. A large proportion of these men under-
went further investigations and 1.4% were diag-
nosed to have prostate cancer, most usually
a localised one. The Quebec-1988 screening trial17
found that screening reduced mortality from 5 per
1000 to 1.3 per 1000 at 8-year follow-up, a 62%relative risk reduction. The human price to pay, of
course, is possibly overdiagnosis and morbidity
from radical local treatment, but it appears that,
at least in theory, a well informed choice could be
available to men.
Breast cancer is the most researched cancer and
benefits from a long history of evolution of its
management. It is a common cause of death among
women aged 45e65, second only to the diseases
caused by smoking. Advanced breast cancer is
almost always fatal and earlier diagnosis appears
to confer a better prognosis. Mechanistic principles
would dictate that detection and removal of breast
cancer early enough would make it curable, or at
least, its treatment less morbid.
Unfortunately, breast cancer does not behave in
a mechanistic fashion and its natural history is still
an enigma.18 A large proportion of normal women
harbour cancers in their breasts e up to a third by
the time they reach 55 years of age e as revealed
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give rise to clinical disease and uncovering the
others with more sensitive imaging would, there-
fore, be unnecessary at best or harmful at worst.
Screening for breast cancer is perhaps the best
demonstration of non-generalisability of screening.
Breast cancer screening can be performed using
X-ray mammography (XRM) and physical examina-
tion. The only trial that tested the benefit of one
over and above the other20,21 found that mammog-
raphy does not add anything to physical breast
examination. The well publicised controversy
about results of randomised trials of mammographic
screening22,23 stems from two factors: the natural
history of breast cancers is not straightforward and
mammography is not a good tool, consequently, the
benefit from screening is exceedingly modest. It
takes about 1500 women to be screened for 10 years
to save one life. Assuming the best possible benefit
from mammography an elegant model has been
recently created.24 Data from this model suggest
that more than half of invasive cancers detected by
screening would never become clinically evident,25
a fact that is never included in the ‘information’
sheet given to women invited to national screening
programme. Mammography is not very sensitive
(sensitivityZ65%).26 So the interval cancer rates
are substantial and these cancers typically have
a poor prognosis. Wisdom of hindsight can pick an
abnormality in a mammogram that was reported as
normal and in a blame-and-shame culture can lead
to very nasty accusations, expensive law-suits and
general discontent. Mammography also has low
specificity. The high rate of recall and false alarm
mean that about one-third (half in the USA) of
women in the UK would be recalled for further tests
during their 15 years of screening programme.
Women are not informed of these figures before
entering the screening programme. So the psycho-
logical impact of these false alarms is consider-
able.27 The phenomenon of post-event consolation
means that these are never considered wrong e
because if the alarm was false, there is relief and
if the alarm is true then there is the undeniable
feeling ‘we caught it early’. But the women did not
consent for all these stresses! The other fact that
remains hidden, more by ignorance than by malice,
is that the diagnosis of ductal carcinoma in situ
(DCIS) was extremely rare before screening mam-
mography. Less than half of DCIS treated with
surgical biopsy progress to invasive carcinoma.28
Left alone, even fewer may have progressed.
Screening mammography does not seem to reduce
the incidence of invasive carcinoma even over a 30-
year period,24,25 suggesting that the effect of
screening mammography and subsequent treatmenton natural history of the disease is small. The
diagnosis by screening, of a breast cancer that
could well have been inconsequential, can have
several repercussions, such as the emotional stress,
social implications and finally the financial issues
such as difficulty in getting insurance, mortgage
and continuing in a well established job. Since we
cannot reliably distinguish good from bad screen
detected cancers, treatment remains aggressive
and sometimes paradoxically so. For example, the
rate of mastectomy can be much higher for screen
detected cancers than for symptomatic cancers.29
So screening mammography does not even reduce
morbidity of treatment. Furthermore, screening
mammography incurs a high opportunity cost. The
billions spent on screening could be better spent on
finding new drugs to treat breast cancer that may
save many more lives.30,31 Arguably, the principle
benefit of screening programmes world over has
been to create better organisation of service de-
livery and increased awareness about breast cancer
that may have led to increased investment into
research.
So should screening for breast cancer be aban-
doned? That may be too extreme. Perhaps, we
should re-examine our premises and tools. Even
with the price of overdiagnosis by an order of 2,
X-ray mammography cannot detect cancer until it
has lived 90% in its natural history (i.e., 28 of 30
doublings).32 This is long after the angiogenic
switch that could start the metastatic process.
Thus, even with a mechanistic theory, the effect of
mammographic screening is unlikely to be large.
Would newer more sensitive screening tools such as
MRI deliver what X-ray mammography did not? In the
UK MARIBS study33 of young high-risk women (BRCA-
1/BRCA-2 mutation carriers), MRI detected twice
the number of cancers as X-ray mammography.
Adding MRI to XRM increased the sensitivity from
40% to 94%. Logic would dictate that this could
save lives, but human biology does not always
follow logic. Secondly, even MRI needs to wait for
increased vascularity to detect a cancer when it
may already be too late because the tumour cells
would have had access to circulation. The oppor-
tunity to test this may not have been lost. A
worldwide (1:4, MRI:control) randomised study that
includes women from countries at all levels of
prosperity could be the only ethical way of
rationing scare healthcare resources. That would
answer the questions whether ‘even earlier’ de-
tection by MRI can favourably alter the natural
history of the breast cancer and, if so at what cost.
Adapting MRI as the standard of care for high-risk
women based on sensitivity results alone would be
unethical especially if it competes for resources
Editorial 111with new biological treatments such as Trastuzu-
mab, that have been proven to save lives.34,35
While women should be well informed about it,
one cannot be too critical about overdiagnosis of
cancer by screening and view it in the proper
perspective. A simple way is to count the numbers
needed to treat (NNT). For example, in large
sentinel node biopsy studies, 26% of clinically
negative axillae harbour involved nodes. If axillary
clearance is acceptable treatment for this group,
then the NNTwould be 4. Similarly, if half of screen
detected cancers would have progress to clinical
cancers, then the NNT for treating a screen de-
tected cancer (as opposed to screening process
itself) is 2. This may be more than symptomatic
disease, but one could argue that it is manifold
smaller than the NNTs used for several other well
accepted interventions such as systemic adjuvant
therapy for cancer or even treatment of hyperten-
sion, which invariably run into 2 or 3 digit numbers.
The concept of screening is based on the logical
axiom ‘‘a stitch in time, saves nine’’. It works well
for machines, but living organisms have evolved to
cope with errors. Many of these errors, therefore,
do not result in disease. We have only just begun
to unravel the subtleties of the human patholog-
ical process and it is easy to fall into the trap of
treating every possible ‘abnormality’ that can be
found. The problem is compounded by newer
imaging techniques and molecular markers that
can find seeds of disease that may never bloom in
the person’s lifetime. The cost of screening is not
just financial, but sociological. Once the diagnosis
of cancer loses all its associated clinical and social
taboos, it would be easier to accept overdiagnosis.
Before any test, that would ‘logically’ save lives, is
accepted for general use it needs to go through the
rigors of the randomised trials process that asks
the right questions e does it really work? And at
what cost? Clinicians and health policy makers
should remember the differential effectiveness
of an apparently universal intervention such as
screening and the high non-apparent costs associ-
ated with it.
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